These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 3122484

  • 1. Evaluation and significance of the degree of pituitary-gonadal inhibition during intranasal administration of buserelin.
    Bourguignon JP, Heinrichs C, Van Vliet G, Vandeweghe M, Vanderschueren-Lodeweyckx M, Malvaux P, Du Caju M, Craen M, Lambrechts L, Delire M.
    Acta Endocrinol (Copenh); 1987 Dec; 116(4):519-25. PubMed ID: 3122484
    [Abstract] [Full Text] [Related]

  • 2. Treatment of central precocious puberty with an intranasal analogue of GnRH (Buserelin).
    Bourguignon JP, Van Vliet G, Vandeweghe M, Malvaux P, Vanderschueren-Lodeweyckx M, Craen M, Du Caju MV, Ernould C.
    Eur J Pediatr; 1987 Nov; 146(6):555-60. PubMed ID: 3123239
    [Abstract] [Full Text] [Related]

  • 3. Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology.
    Heinrichs C, Craen M, Vanderschueren-Lodeweyckx M, Malvaux P, Fawe L, Bourguignon JP.
    Acta Paediatr; 1994 Jun; 83(6):627-33. PubMed ID: 7919761
    [Abstract] [Full Text] [Related]

  • 4. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.
    Partsch CJ, Hümmelink R, Peter M, Sippell WG, Oostdijk W, Odink RJ, Drop SL.
    Horm Res; 1993 Jun; 39(3-4):111-7. PubMed ID: 8262471
    [Abstract] [Full Text] [Related]

  • 5. Intranasal and subcutaneous treatment of central precocious puberty in both sexes with a long-acting analog of luteinizing hormone-releasing hormone.
    Luder AS, Holland FJ, Costigan DC, Jenner MR, Wielgosz G, Fazekas AT.
    J Clin Endocrinol Metab; 1984 Jun; 58(6):966-72. PubMed ID: 6427266
    [Abstract] [Full Text] [Related]

  • 6. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A, Scheike T, Nielsen CT, Krabbe S, Müller J, Skakkebaek NE.
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [Abstract] [Full Text] [Related]

  • 7. The treatment of central precocious puberty using an intranasal LHRH analogue (buserelin).
    Stanhope R, Adams J, Brook CG.
    Clin Endocrinol (Oxf); 1985 Jun; 22(6):795-806. PubMed ID: 3926352
    [Abstract] [Full Text] [Related]

  • 8. Long-term treatment of central precocious puberty with an intranasal LHRH analogue: control of pituitary function by urinary gonadotropins.
    Rime JL, Zumsteg U, Blumberg A, Hadziselimovic F, Girard J, Zurbrügg RP.
    Eur J Pediatr; 1988 Apr; 147(3):263-9. PubMed ID: 3134243
    [Abstract] [Full Text] [Related]

  • 9. Suppression of the pituitary-gonadal axis in children with central precocious puberty: effects on growth, growth hormone, insulin-like growth factor-I, and prolactin secretion.
    Sklar CA, Rothenberg S, Blumberg D, Oberfield SE, Levine LS, David R.
    J Clin Endocrinol Metab; 1991 Oct; 73(4):734-8. PubMed ID: 1909701
    [Abstract] [Full Text] [Related]

  • 10. Suppression of puberty in girls with short-acting intranasal versus subcutaneous depot GnRH agonist.
    Tuvemo T, Gustafsson J, Proos LA, Swedish Growth Hormone Group.
    Horm Res; 2002 Oct; 57(1-2):27-31. PubMed ID: 12006716
    [Abstract] [Full Text] [Related]

  • 11. GnRH agonist stimulation of the pituitary-gonadal axis in children: age and sex differences in circulating inhibin-B and activin-A.
    Elsholz DD, Padmanabhan V, Rosenfield RL, Olton PR, Phillips DJ, Foster CM.
    Hum Reprod; 2004 Dec; 19(12):2748-58. PubMed ID: 15513981
    [Abstract] [Full Text] [Related]

  • 12. Long-term results of GnRH analogue (Buserelin) treatment in girls with central precocious puberty.
    Brauner R, Thibaud E, Bischof P, Sizonenko PC, Rappaport R.
    Acta Paediatr Scand; 1985 Nov; 74(6):945-9. PubMed ID: 3937430
    [Abstract] [Full Text] [Related]

  • 13. Treatment of precocious puberty using an intranasal luteinizing hormone-releasing hormone analogue: Buserelin.
    Low LC, Wang C, Cheung PT, Chan FL.
    Aust Paediatr J; 1989 Oct; 25(5):274-8. PubMed ID: 2511831
    [Abstract] [Full Text] [Related]

  • 14. Long-term follow-up and final height in girls with central precocious puberty treated with luteinizing hormone-releasing hormone analogue nasal spray.
    Cacciari E, Cassio A, Balsamo A, Colli C, Cicognani A, Pirazzoli P, Tani G, Brondelli L, Mandini M, Bovicelli L.
    Arch Pediatr Adolesc Med; 1994 Nov; 148(11):1194-9. PubMed ID: 7921123
    [Abstract] [Full Text] [Related]

  • 15. [Comparison between complete and incomplete suppression of the hypophyseal-gonadal axis in girls with central precocious puberty: effect on growth and prospective final height].
    Partsch CJ, Hümmelink R, Sippell WG, Oostdijk W, Odink RJ, Drop SL.
    Monatsschr Kinderheilkd; 1993 Dec; 141(12):935-9. PubMed ID: 8114776
    [Abstract] [Full Text] [Related]

  • 16. [Subcutaneous and intranasal use of a LH-RH analog in the treatment of girls with central precocious puberty].
    Fideleff HL, Boquete HR, Azaretzky M, Damilano S, Cagide AL, Levalle O.
    Medicina (B Aires); 1989 Dec; 49(6):567-72. PubMed ID: 2518644
    [Abstract] [Full Text] [Related]

  • 17. [Monitoring the treatment of precocious puberty with a GnRH-analog (buserelin): comparison of the GnRH-test with nocturnal pulsatility of LH, testosterone and 17-beta-estradiol].
    Radetti G, Pasquino B, Castellan C, Gentili L, Mengarda G.
    Pediatr Med Chir; 1991 Dec; 13(5):471-4. PubMed ID: 1788106
    [Abstract] [Full Text] [Related]

  • 18. LH-RH agonistic analog (buserelin) treatment of precocious puberty: collaborative study in Japan.
    Suwa S, Hibi I, Kato K, Nakazima H.
    Acta Paediatr Jpn; 1988 Dec; 30 Suppl():176-84. PubMed ID: 3146872
    [No Abstract] [Full Text] [Related]

  • 19. Luteinizing hormone-releasing hormone analogue (Buserelin) treatment for central precocious puberty: a multi-centre trial.
    Werther GA, Warne GL, Ennis G, Gold H, Silink M, Cowell CT, Quigley C, Howard N, Antony G, Byrne GC.
    J Paediatr Child Health; 1990 Feb; 26(1):4-8. PubMed ID: 2109996
    [Abstract] [Full Text] [Related]

  • 20. Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model.
    Roth C, Leonhardt S, Seidel C, Luft H, Wuttke W, Jarry H.
    Pediatr Res; 2000 Oct; 48(4):468-74. PubMed ID: 11004237
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.